游离DNA用于检测复发/难治性多发性骨髓瘤中出现的治疗失败
本研究探讨游离DNA(cfDNA)低深度全基因组测序(LPWGS)在复发/难治性多发性骨髓瘤(RRMM)中的预测价值。探索性队列16例中cfDNA阳性(肿瘤分数≥10%)与更短无进展生存期(PFS)相关;II期临床试验45例RRMM患者86份样本中,治疗2周期后cfDNA阳性者PFS为1.6个月,阴性者为17.6个月(HR 7.6,P<0.0001)。cfDNA为独立风险因素(HR 96.6,P=6.92e-05),可在IMWG标准相同缓解患者中进一步区分PFS较差者。
要点
- 治疗2周期后cfDNA阳性者PFS 1.6个月,阴性者17.6个月(HR 7.6,P<0.0001)。
- 多因素模型证实cfDNA为独立风险因素(HR 96.6,P=6.92e-05)。
- cfDNA可在IMWG标准相同缓解患者中额外区分PFS较差者。
核心结论
- 治疗后可检测到MM来源cfDNA提示 substantial 肿瘤负荷,可独立预测较差PFS,可能为标准化疗效参数提供补充,比目前可行的方法更早识别治疗反应差的患者。
研究设计与样本
- 探索性测试队列纳入16例接受多种方案积极治疗的RRMM患者,采用cfDNA低深度全基因组测序(LPWGS)检测,cfDNA阳性定义为肿瘤分数≥10%。
- 前瞻性II期临床试验(NCT02718833)纳入45例RRMM患者,接受埃罗妥珠单抗、泊马度胺、硼替佐米和地塞米松治疗,采集86份样本评估cfDNA预测价值。
主要发现
- 探索性测试队列16例中,cfDNA阳性与显著更短PFS相关。
- II期试验中,治疗2周期后cfDNA肿瘤阳性者PFS为1.6个月,阴性者为17.6个月(HR 7.6,P<0.0001)。
- 多因素风险模型证实cfDNA为独立风险因素(HR 96.6,P=6.92e-05)。
- cfDNA与血清游离轻链及骨髓相关,并可在IMWG标准相同缓解患者中额外区分PFS较差者。
关键数值与推荐
- cfDNA阳性定义为LPWGS检测肿瘤分数≥10%。
- 治疗2周期后cfDNA阳性者PFS 1.6个月,阴性者17.6个月(HR 7.6,P<0.0001)。
- 多因素分析中cfDNA独立风险因素HR 96.6(P=6.92e-05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 探索性测试队列仅16例,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Interrogation of cell-free DNA (cfDNA) represents an emerging approach to non-invasively estimate disease burden in multiple myeloma (MM). Here, we examined low-pass whole genome sequencing (LPWGS) of cfDNA for its predictive value in relapsed/ refractory MM (RRMM). We observed that cfDNA positivity, defined as ≥10% tumor fraction by LPWGS, was associated with significantly shorter progression-free survival (PFS) in an exploratory test cohort of 16 patients who were actively treated on diverse regimens. We prospectively determined the predictive value of cfDNA in 86 samples from 45 RRMM patients treated with elotuzumab, pomalidomide, bortezomib, and dexamethasone in a phase II clinical trial (NCT02718833). PFS in patients with tumor-positive and -negative cfDNA after two cycles of treatment was 1.6 and 17.6 months, respectively (HR 7.6, P < 0.0001). Multivariate hazard modelling confirmed cfDNA as independent risk factor (HR 96.6, P = 6.92e-05). While correlating with serum-free light chains and bone marrow, cfDNA additionally discriminated patients with poor PFS among those with the same response by IMWG criteria. In summary, detectability of MM-derived cfDNA, as a measure of substantial tumor burden with therapy, independently predicts poor PFS and may provide refinement for standard-of-care response parameters to identify patients with poor response to treatment earlier than is currently feasible.
引用
- Waldschmidt JM, Yee AJ, Vijaykumar T, et al. Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia. 2022. PMID: 35027656. doi:10.1038/s41375-021-01492-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。